ExchangeDEX+

Buy Crypto Markets Spot FuturesGOLD Earn Event Center

Commodity Zero-Fee Gala

Editas Medicine, Inc. (EDIT)

NASDAQ

$1.76

$+0.08

(+4.76%)

Editas Medicine, Inc. (EDIT) Live Price Chart

Page last updated: 2026-02-14 00:29:00

Key Market Data

Market Cap	$171.81M
Open	$1.70
High	$99.95
Low	$0.91
Previous Close	$1.68
Price Change	$+0.08
Percentage Change	+4.76%
Volume	1M

Editas Medicine, Inc. (EDIT) Stock Price Today

Editas Medicine, Inc. (EDIT) is currently trading at $1.76 as of 2026-02-14 00:29:00, reflecting a +4.76% move ($+0.08) from the previous close.

In the short term, the stock has returned -1,330.05% over the past four weeks. Over the last 12 months, Editas Medicine, Inc. has recorded a +27.54% price change, indicating a strong performance relative to the broader market.

Editas Medicine, Inc. (EDIT) 7-Day Stock Price Changes

Over the past seven days, Editas Medicine, Inc. has traded within a short-term range shaped by market sentiment in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. During this period, the stock moved from its previous closing price of $1.79 to the latest recorded price of $1.76, reflecting an intraday change of +4.76%. Daily movements highlight shifts in trading volume (1,330,218), investor positioning, and reactions to macroeconomic updates.

From a momentum standpoint, EDIT has delivered a -1,330.05% return over the past month and a +27.54% change in the last 12 months, indicating a strong trend relative to its broader sector peers.

How to Buy Editas Medicine, Inc. (EDIT)

You can buy and trade EDIT on MEXC in three simple steps:

Step 1: Create and Verify Your MEXC Account

Sign up on MEXC and complete the required identity verification (KYC). This ensures full access to trading features and secure funding options.

Step 2: Deposit Funds Into Your Account

Choose your preferred payment method to add USDT or other supported assets to your MEXC wallet. Depositing crypto is the fastest way to get started.

Step 3: Search for EDIT and Execute Your Trade

Open the trading page, enter EDIT in the search bar, select the amount of EDIT you would like to purchase. Place a market order for instant execution or a limit order to buy at your target price.

What is Editas Medicine, Inc. (EDIT)?

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	226
Sector	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Website	https://www.editasmedicine.com

Frequently Asked Questions (FAQ)

1.What is the current share price of Editas Medicine, Inc.?

The latest trading price for Editas Medicine, Inc. (Common Stock) is $ 1.76, compared with a previous closing price of $ 1.68. That means the stock has moved +4.76% so far today. Intraday price updates and recent trading activity for EDIT can be tracked on the live chart and quote section on this page.

2.Is Editas Medicine, Inc. stock going up or down?

Looking at recent performances, EDIT has returned -1,330.05% over the past month, -33.08% over the last six months and +27.54% over the past year. These figures capture share-price changes only, not the impact of dividends. Together they describe strong price momentum for Editas Medicine, Inc. stock, but keep in mind that past returns do not guarantee future results.

3.Where does EDIT currently sit relative to its 52-week high and low?

In the most recent 52-week period, Editas Medicine, Inc. has traded between a low of $ 0.91 and a high of $ 4.54. This 52-week range helps show where today's share price sits relative to its recent highs and lows, and is often used by investors to judge stock volatility, potential support and resistance levels, and whether EDIT is currently nearer the top or the bottom of its one-year trading band.

4.How is Editas Medicine, Inc. classified by sector and industry?

Editas Medicine, Inc. is classified in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. In practice, this means Editas Medicine, Inc. is grouped with other companies that serve similar end-markets and operate under comparable competitive and regulatory conditions. For investors, knowing EDIT’s sector helps with portfolio diversification, peer comparisons, and understanding how broader trends affecting the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector could influence Editas Medicine, Inc.’s performance.

5.Where is Editas Medicine, Inc. listed and how large is it by market value?

Editas Medicine, Inc. is listed on the NASDAQ stock exchange in United States. Based on a market capitalization of $ 171.81M, the company is classified as a Small-cap stock. Market cap gives a quick sense of Editas Medicine, Inc.'s size and importance in the equity market and is often used by investors and index providers when constructing portfolios or benchmarks.

6.What does EDIT's EPS tell investors about its profitability?

Trailing-twelve-month EPS of $ -2.05 summarises how much profit Editas Medicine, Inc. has generated per share over the last year. Rising EPS over time can signal improving profitability or effective share repurchases, while flat or declining EPS may point to slower growth or margin pressure. EPS is a key input into valuation metrics such as P/E and is often monitored closely around earnings announcements.

7.How can I track Editas Medicine, Inc.'s financial performance over time?

To follow Editas Medicine, Inc.'s financial performance, investors typically review its quarterly and annual reports, which include detailed income statements, balance sheets and cash-flow statements. Combining these filings with key market data shown on this page—such as share price trends, P/E and dividend yield—provides a more complete view of how EDIT is performing and how the market is responding.

8.When is Editas Medicine, Inc. expected to report earnings?

Editas Medicine, Inc.'s next scheduled earnings release is currently expected on -- (the date may be updated by the company). Earnings announcements often act as important catalysts for EDIT, as they provide updated information on revenue, profitability and management's outlook.

9.What usually comes out in Editas Medicine, Inc.'s earnings reports?

Editas Medicine, Inc.'s earnings reports typically include headline figures such as revenue, net income and EPS, along with commentary on segment performance, margins, cash flow and guidance for future periods. Investors compare these results with market expectations and prior periods to assess whether EDIT is meeting, beating or missing expectations.

10.How can I stay informed about Editas Medicine, Inc.'s results and guidance?

You can stay up to date on Editas Medicine, Inc. by reviewing its quarterly earnings releases, listening to or reading transcripts of earnings calls, and following company news and filings. Pairing this fundamental information with the price and return data for EDIT on this page helps you see how new information is being reflected in the stock.

11.Does Editas Medicine, Inc. pay a regular cash dividend to its shareholders?

Editas Medicine, Inc. Non-paying. Based on the latest information, the stock has an indicated annual cash dividend of -- per share and a current dividend yield of 0 at the recent share price. Dividends are typically paid --, although the board can change the dividend policy at any time. Income-focused investors often monitor EDIT's dividend level, payment frequency and any announcements about future dividends when assessing the stock's appeal as a dividend-paying investment.

12.What are the current dividend yield and dividend payout ratio for EDIT?

Based on the latest earnings data, EDIT has a dividend yield of 0 and a dividend payout ratio of 0. The dividend yield shows how much cash return an investor receives from dividends each year relative to the current share price, helping assess whether Editas Medicine, Inc. is an attractive income stock. The dividend payout ratio measures what percentage of earnings Editas Medicine, Inc. distributes to shareholders as dividends versus how much it retains to reinvest in the business, which is an important indicator of dividend sustainability and room for future dividend growth.

13.What kind of business is Editas Medicine, Inc.?

Editas Medicine, Inc. is a publicly traded company in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry within the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. It generates revenue from products and services related to this core business area, and investors can find a detailed description of its operations, strategy and geographic exposure in the company's annual report and other regulatory filings.

14.How is EDIT valued in terms of P/E ratio and EPS?

Editas Medicine, Inc. currently trades at a price-to-earnings (P/E) ratio of --, based on trailing-twelve-month earnings per share (EPS) of $ -2.05. P/E is calculated by dividing the share price by EPS and shows how much investors are paying today for each unit of Editas Medicine, Inc.'s earnings. Comparing EDIT's P/E and EPS to those of other BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) companies can help investors judge whether its valuation looks rich or attractive.

Explore More US Stocks

Stocks in the Same Sector

Browse other US stocks in the same sector as Editas Medicine, Inc.

The Walt Disney Company

DIS

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

CHR

Innovation Beverage Group Limited

IBG

Lumentum Holdings Inc.

LITE

Top Gainers

Browse today's leading gainers in the US stock market

Digital Brands Group, Inc.

DBGI

Founder Group Limited

FGL

JIADE LIMITED

JDZG

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

BTC

ETH

SOL

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

EDIT-to-USD Calculator

Amount

EDIT

USD

1 EDIT = 1.76 USD